Role of Psychosomatic Symptoms in COVID-19 Vaccine Hesitancy-Reference-Cited by-同舟云学术

Role of Psychosomatic Symptoms in COVID-19 Vaccine Hesitancy

Published:2023-04-30 Issue:5 Volume:11 Page:922
ISSN:2076-393X
Container-title:Vaccines
language:en
Short-container-title:Vaccines

Author:

Desai Saral¹^ORCID,Kainth Tejasvi²,Yadav Garima³^ORCID,Kochhar Hansini⁴,Srinivas Sushma⁵,Kamil Saher⁶,Du Wei⁷⁸

Affiliation:

1. Department of Psychiatry, Tower Health-Phoenixville Hospital, Phoenixville, PA 19460, USA

2. Department of Psychiatry, Stony Brook University, Stony Brook, NY 11794, USA

3. Department of Psychiatry, Bronx Care Health System, Bronx, NY 10456, USA

4. Department of Psychiatry, Maimonides Medical Center, Brooklyn, NY 11219, USA

5. Department of Psychiatry, A.J. Institute of Medical Sciences and Research Center, Manglore 575004, India

6. Department of Pediatrics, Dell Children’s Medical Center, Austin, TX 78723, USA

7. Academic Affairs, Tower Health, West Reading, PA 19611, USA

8. Department of Psychiatry, Drexel University College of Medicine, Philadelphia, PA 19102, USA

Abstract

Vaccination against COVID-19 is one of the highly effective preventative strategies to reduce morbidity and mortality associated with COVID-19 infection. The rapid approval of COVID-19 vaccination due to the raging pandemic, media coverage, anti-vaccination groups, and concerns about adverse effects associated with vaccination has given rise to COVID-19 vaccine hesitancy. Current evidence suggests that psychosomatic and nocebo-related adverse effects account for a significant proportion of common adverse effects following COVID-19 vaccination. The most common adverse effects are headache, fatigue, and myalgia, which are highly prone to nocebo effects. In our review article, we discuss the role of psychosomatic and nocebo effects in COVID-19 vaccination-related hesitancy, predictors of such effects, and strategies to reduce vaccine hesitancy. General education regarding psychosomatic and nocebo effects and specialized education for at-risk populations may reduce psychosomatic and nocebo-related adverse effects following COVID-19 vaccination, ultimately reducing hesitancy.

Publisher

MDPI AG

Subject

Pharmacology (medical),Infectious Diseases,Drug Discovery,Pharmacology,Immunology

Link

https://www.mdpi.com/2076-393X/11/5/922/pdf

Reference60 articles.

1. (2022, November 15). WHO Coronavirus (COVID-19) Dashboard. Available online: https://covid19.who.int/.

2. Fleming, K.E. (2022, November 27). MDCOVID-19 Epidemiology and Vaccination Rates in the United States, Available online: https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2022-07-19/02-covid-fleming-dutra-508.pdf.

3. (2023, March 04). Office of the Commissioner FDA Approves First COVID-19 Vaccine, Available online: https://www.fda.gov/news-events/press-announcements/fda-approves-first-covid-19-vaccine.

4. Mental Health Issues During and after COVID-19 Vaccine Era;Pandey;Brain Res. Bull.,2021

5. Psychological and Behavioral Predictors of Vaccine Efficacy: Considerations for COVID-19;Madison;Perspect. Psychol. Sci.,2021

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Factors Influencing the Healthcare Workers’ Willingness to Receive the COVID-19 Booster Dose in Tuscany (Italy);Vaccines;2023-11-24